These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12563)

  • 1. [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].
    Balant L; Gorgia A; Tschopp JM; Revillard C; Fabre J
    Schweiz Med Wochenschr; 1976 Oct; 106(41):1403-7. PubMed ID: 12563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].
    Tschopp JM; Gorgia A; Balant L; Revillard C; Francis RJ; Fabre FJ
    Schweiz Med Wochenschr; 1978 May; 108(20):756-64. PubMed ID: 26114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of tolamolol and bufuralol on the arterial blood pressure and plasma renin activity. Contribution to the study of beta-blocking agents action mechanisms (author's transl)].
    Rostan A
    Schweiz Rundsch Med Prax; 1978 Jan; 67(1):27-35. PubMed ID: 23523
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings: Preliminary studies of Ro 3-3528, a beta-adrenoceptor-blocking agent, in man.
    Hicks DC; Phillips EM
    Br J Pharmacol; 1972 Feb; 44(2):377P-378P. PubMed ID: 4148922
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
    Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Thebault JJ; Trocherie S; Morselli PL
    Arzneimittelforschung; 1980; 30(11):1912-6. PubMed ID: 6109538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.
    Wiedemann I; Peil H; Justus H; Adamus S; Brantl V; Lohmann H
    Arzneimittelforschung; 1985; 35(6):964-9. PubMed ID: 2862877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man.
    Gugler R; Kreis L; Dengler HJ
    Arzneimittelforschung; 1975 Jul; 25(7):1067-72. PubMed ID: 241357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
    Bonelli J; Hitzenberger G; Krause W; Wendt H; Speck U
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):169-76. PubMed ID: 6103882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic characterization of bufuralol-HCl and pindolol based on the competitive effects of isoproterenol.
    Magometschnigg D; Bonelli J; Kaik G
    Int J Clin Pharmacol Biopharm; 1979 Nov; 17(11):429-32. PubMed ID: 41815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
    Balant L; Gorgia A; Marmy A; Tschopp JM
    Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of renal insufficiency on the hepatic clearance of some drugs.
    Balant LP; Dayer P; Fabre J
    Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man.
    Houin G; Barre J; Jeanniot JP; Ledudal P; Cautreels W; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):175-83. PubMed ID: 6149195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent.
    Haustein KO; Fritzsche K
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):392-5. PubMed ID: 6117520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of dl- and l-moprolol in the human.
    Harvengt C; Desager JP
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):57-61. PubMed ID: 6120901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical investigation of o-(2-hydroxy-3-(tert.-butylamino)-propoxy)-benzonitrile under glucose load by means of continuous recording].
    Regula H; Papner B
    Arzneimittelforschung; 1974 Sep; 24(9):1328-30. PubMed ID: 4154767
    [No Abstract]   [Full Text] [Related]  

  • 17. Decrease of peripheral resistance after acute intravenous application of a new beta-receptor blocking agents, bufuralol HCl.
    Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G; Korn A
    Int J Clin Pharmacol Biopharm; 1978 Feb; 16(2):54-8. PubMed ID: 24595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of beta-blocking activity of trimepranol in man.
    Pentikäinen PJ; Neuvonen PJ; Penttilä A
    Int J Clin Pharmacol Biopharm; 1978 Jun; 16(6):279-84. PubMed ID: 27464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic control of bufuralol metabolism in man.
    Dayer P; Balant L; Courvoisier F; Kupfer A; Kubli A; Gorgia A; Fabre J
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):73-7. PubMed ID: 6121708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115) 2. Excretion, blood level and distribution of the 14C-labeled compound in the rat].
    Klemm W; Wenzel A
    Pharmazie; 1975 Oct; 30(10):675-7. PubMed ID: 695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.